BCM
DNLI icon

Bayesian Capital Management’s Denali Therapeutics DNLI Stock Holding History

Bayesian Capital Management’s Portfolio DNLI Stock Details DNLI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-10,130
Closed -$138K – 623
2025
Q1 		$138K Sell
10,130
-8,690
-46% -$167K 0.02% 523
2024
Q4 		$384K Buy
18,820
+10,820
+135% +$277K 0.05% 433
2024
Q3 		$233K Sell
8,000
-42,500
-84% -$1.05M 0.03% 533
2024
Q2 		$1.17M Buy
50,500
+28,700
+132% +$551K 0.13% 202
2024
Q1 		$447K Buy
+21,800
New +$410K 0.04% 462
2023
Q4 		– Sell
-13,942
Closed -$288K – 819
2023
Q3 		$288K Buy
+13,942
New +$354K 0.03% 477

Other funds holding DNLI

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
UBS AM
UBS AM Chicago, Illinois $550B AUM 43.33% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Temasek Holdings
Temasek Holdings Singapore $37.3B AUM 12.6% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Bayesian Capital Management's DNLI Position: Q2 2025 in Review

Bayesian Capital Management sold out of Denali Therapeutics (DNLI) in Q2 2025, closing a stake of 10,130 shares — an estimated $138K sold.

Bayesian Capital Management first reported a position in DNLI in Q3 2023 and held it in 6 quarters. The position peaked at $1.17M in Q2 2024. 230 funds tracked by Wall St. Rank hold DNLI as of Q2 2025.

  • Bayesian Capital Management reported no remaining Denali Therapeutics position as of Q2 2025 after selling out during the quarter.
  • Bayesian Capital Management sold 10,130 Denali Therapeutics shares in Q2 2025, an estimated $138K.
  • Bayesian Capital Management first reported a position in Denali Therapeutics in Q3 2023 and held it in 6 quarters.
  • Bayesian Capital Management's Denali Therapeutics position peaked at $1.17M in Q2 2024.
  • 230 funds tracked by Wall St. Rank held Denali Therapeutics as of Q2 2025.

Based on Bayesian Capital Management's 13F filing for Q2 2025, filed 14 Aug 2025.